Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > C Reactive Protein

C Reactive Protein

C-reactive protein (CRP) is a sensitive biomarker of inflammation and infection.
It is produced by the liver in response to various stimuli, such as tissue injury, infection, and inflammation.
Measuring CRP levels can help diagnose and monitor a variety of health conditions, including cardiovascular disease, rheumatoid arthritis, and cancer.
PubCompare.ai, an AI-driven platform, can optimize CRP research by locating protocols from literature, preprints, and patents, and using AI-driven comparisons to identify the best protocols and products.
This can improve research outcomes and reproducibilty.
Whith PubCompare.ai's powerful tools and features, researchers can enhance their CRP studies and gain valuable insights.

Most cited protocols related to «C Reactive Protein»

1
Epidemiological Analysis of Early COVID-19 Cases
Cited 213 times
We obtained the medical records and compiled data for hospitalized patients and outpatients with laboratory-confirmed Covid-19, as reported to the National Health Commission between December 11, 2019, and January 29, 2020; the data cutoff for the study was January 31, 2020. Covid-19 was diagnosed on the basis of the WHO interim guidance.14 A confirmed case of Covid-19 was defined as a positive result on high-throughput sequencing or real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens.1 (link) Only laboratory-confirmed cases were included in the analysis.
We obtained data regarding cases outside Hubei province from the National Health Commission. Because of the high workload of clinicians, three outside experts from Guangzhou performed raw data extraction at Wuhan Jinyintan Hospital, where many of the patients with Covid-19 in Wuhan were being treated.
We extracted the recent exposure history, clinical symptoms or signs, and laboratory findings on admission from electronic medical records. Radiologic assessments included chest radiography or computed tomography (CT), and all laboratory testing was performed according to the clinical care needs of the patient. We determined the presence of a radiologic abnormality on the basis of the documentation or description in medical charts; if imaging scans were available, they were reviewed by attending physicians in respiratory medicine who extracted the data. Major disagreement between two reviewers was resolved by consultation with a third reviewer. Laboratory assessments consisted of a complete blood count, blood chemical analysis, coagulation testing, assessment of liver and renal function, and measures of electrolytes, C-reactive protein, procalcitonin, lactate dehydrogenase, and creatine kinase. We defined the degree of severity of Covid-19 (severe vs. nonsevere) at the time of admission using the American Thoracic Society guidelines for community-acquired pneumonia.15 (link)All medical records were copied and sent to the data-processing center in Guangzhou, under the coordination of the National Health Commission. A team of experienced respiratory clinicians reviewed and abstracted the data. Data were entered into a computerized database and cross-checked. If the core data were missing, requests for clarification were sent to the coordinators, who subsequently contacted the attending clinicians.
Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y, & Zhong N.S. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine.
Publication 2020
Biological Assay Blood Chemical Analysis Complete Blood Count COVID 19 C Reactive Protein Creatine Kinase Electrolytes Kidney Lactate Dehydrogenase Liver Nose Outpatients Patients Pharynx Physicians Pneumonia Procalcitonin Radiography, Thoracic Radionuclide Imaging Real-Time Polymerase Chain Reaction Respiratory Rate Reverse Transcriptase Polymerase Chain Reaction RNA-Directed DNA Polymerase X-Ray Computed Tomography
2
Genetic Correlations Between Parkinson's and Traits
Cited 72 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019
Biological Markers Brain Cognition C Reactive Protein Cytokine Dietary Supplements Genome-Wide Association Study Putamen Toxic Epidermal Necrolysis
3
Dietary Inflammation and CRP Levels
Cited 72 times
Summary statistics were used to describe the study population at baseline separately for both 24HR and 7DDR subsets (as the numbers of participants with complete data from each were unequal; n 495 and n 559, respectively). Comparisons of baseline characteristics by sex were made using χ2 tests for categorical variables and two-sample t tests for continuous variables. DII was converted to tertiles and tests for trend across DII tertiles were carried out for age, smoking status, hs-CRP, BMI, MET/d, LDL-cholesterol and HDL-cholesterol. Generalized linear mixed models (proc GLIMMIX in SAS) were used for more complex analyses. Here, we used a compound symmetry covariance matrix to account for the dependence of observations made on the same individuals. The primary outcome variable for this analysis was hs-CRP, which was dichotomized to ≤3 mg/l and >3 mg/l, and the odds of elevated hs-CRP (>3 mg/l) was determined. Values of hs-CRP >10 mg/l were excluded from the total number of observations because this may be a result of acute inflammation; only sixty-five such values (3% of the total) were excluded from the total of 2165 available hs-CRP measures as a consequence of this(60 (link)). The primary independent variable was the score obtained from the DII and tertiles of DII. Both unadjusted and adjusted analyses were carried out. We also tested for effect modification between DII score and categories of BMI, age and infection status by including interaction terms in the model. Variables controlled in analyses were age, sex, race, BMI, smoking status, alcohol consumption status, physical activity, marital status, HDL-cholesterol, total cholesterol, anti-inflammatory medication use, light season, herbal supplement use, and a variable indicating if the participant had an infection during the study quarter. Race was dichotomized into ‘White’ and ‘Other’ because 90% of the study population was White. BMI was categorized into normal weight (18·5 to <25·0 kg/m2), overweight (25·0 to <30·0 kg/m2) and obese (≥30·0kg/m2). Participants considered underweight (<18·5 kg/m2) were excluded from analysis. Smoking status was dichotomized as yes/no. Level of education was categorized into high-school graduate or less, vocational/trade and some college, and college graduate or more. Marital status was categorized into single, married, living with a partner, separated, divorced or widowed. Total cholesterol and HDL-cholesterol were left as continuous variables. Seasons were categorized using the ‘light season’ definition centred at the equinoxes/solstices (winter: 6 November to 4 February; spring: 5 February to 6 May; summer: 7 May to 5 August; and autumn: 6 August to 5 November). Participants who reported having arthritis were excluded from analysis. Also, observations missing hs-CRP were excluded from analysis. All data analyses were performed using the SAS® statistical software package version 9·2.
Shivappa N., Steck S.E., Hurley T.G., Hussey J.R., Ma Y., Ockene I.S., Tabung F, & Hébert J.R. (2013). A population-based dietary inflammatory index predicts levels of C-reactive protein in the Seasonal Variation of Blood Cholesterol Study (SEASONS). Public Health Nutrition, 17(8), 1825-1833.
Publication 2013
Anti-Inflammatory Agents Arthritis Cholesterol Cholesterol, beta-Lipoprotein C Reactive Protein Herbal Supplements High Density Lipoprotein Cholesterol Infection Inflammation Light Obesity
4
Validating a Metabolic Syndrome Severity Score
Cited 62 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Adolescent Adult Age Groups BLOOD Cerebrovascular Accident Child Congestive Heart Failure C Reactive Protein Determination, Blood Pressure Diabetes Mellitus Ethnicity Feelings Glucose Heart Disease, Coronary High Density Lipoprotein Cholesterol Hispanics Homeostasis Households Hypolipidemic Agents Insulin Insulin Resistance Lipids Metabolic Syndrome X Mexican Americans Myocardial Infarction Obesity Pharmaceutical Preparations Phlebotomy Plant Roots Plasma Population Group Pressure, Diastolic Racial Groups Sulfur Surrogate Markers Triglycerides Uric Acid Waist Circumference
5
Prognostic Factors in Advanced Cancer
Cited 42 times
Data are presented as median and range. Grouping of the variables age, tumour type, performance status (ECOG), haemoglobin, white cell count and albumin was carried out using standard thresholds (Paesmans et al, 1997; Herndon et al, 1999 (link)). C-reactive protein concentrations were also grouped (⩽10/>10 mg l−l) as previously described (O'Gorman et al, 2000 (link)). Prognostic scores were constructed by assigning one point for each of the following criteria: stage IV, ECOG 2–4, albumin <35 g l−l and C-reactive protein >10 mg l−l. Cumulative scores were obtained by combining C-reactive protein with each of the other variables.
Univariate survival analysis was performed using the Kaplan–Meier method. Multivariate survival analysis and calculation of hazard ratios (HR) were performed using the Cox regression analysis with prognostic scores as covariates. Deaths up to 31 January 2003 were included in the analysis. Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).
Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J, & Dunlop D.J. (2003). Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. British Journal of Cancer, 89(6), 1028-1030.
Full text: Click here
Publication 2003
Albumins C Reactive Protein Electrocorticography Hemoglobin Leukocyte Count Neoplasms

Most recents protocols related to «C Reactive Protein»

1
Ingestible Device for Ulcerative Colitis Treatment
Not available on PMC !

Example 12

As a proof of concept, the patient population of this study is patients that (1) have moderate to severe ulcerative colitis, regardless of extent, and (2) have had an insufficient response to a previous treatment, e.g., a conventional therapy (e.g., 5-ASA, corticosteroid, and/or immunosuppressant) or a FDA-approved treatment. In this placebo-controlled eight-week study, patients are randomized. All patient undergo a colonoscopy at the start of the study (baseline) and at week 8. Patients enrolled in the study are assessed for clinical status of disease by stool frequency, rectal bleeding, abdominal pain, physician's global assessment, and biomarker levels such as fecal calprotectin and hsCRP. The primary endpoint is a shift in endoscopy scores from Baseline to Week 8. Secondary and exploratory endpoints include safety and tolerability, change in rectal bleeding score, change in abdominal pain score, change in stool frequency, change in partial Mayo score, change in Mayo score, proportion of subjects achieving endoscopy remission, proportion of subjects achieving clinical remission, change in histology score, change in biomarkers of disease such as fecal calprotectin and hsCRP, level of adalimumab in the blood/tissue/stool, change in cytokine levels (e.g., TNFα, IL-6) in the blood and tissue.

FIG. 72 describes an exemplary process of what would occur in clinical practice, and when, where, and how the ingestible device will be used. Briefly, a patient displays symptoms of ulcerative colitis, including but not limited to: diarrhea, bloody stool, abdominal pain, high c-reactive protein (CRP), and/or high fecal calprotectin. A patient may or may not have undergone a colonoscopy with diagnosis of ulcerative colitis at this time. The patient's primary care physician refers the patient. The patient undergoes a colonoscopy with a biopsy, CT scan, and/or MRI. Based on this testing, the patient is diagnosed with ulcerative colitis. Most patients are diagnosed with ulcerative colitis by colonoscopy with biopsy. The severity based on clinical symptoms and endoscopic appearance, and the extent, based on the area of involvement on colonoscopy with or without CT/MRI is documented. Treatment is determined based on diagnosis, severity and extent.

For example, treatment for a patient that is diagnosed with ulcerative colitis is an ingestible device programmed to release a single bolus of a therapeutic agent, e.g., 40 mg adalimumab, in the cecum or proximal to the cecum. Prior to administration of the treatment, the patient is fasted overnight and is allowed to drink clear fluids. Four hours after swallowing the ingestible device, the patient can resume a normal diet. An ingestible device is swallowed at the same time each day. The ingestible device is not recovered.

In some embodiments, there may be two different ingestible devices: one including an induction dose (first 8 to 12 weeks) and a different ingestible device including a different dose or a different dosing interval.

In some examples, the ingestible device can include a mapping tool, which can be used after 8 to 12 weeks of induction therapy, to assess the response status (e.g., based on one or more of the following: drug level, drug antibody level, biomarker level, and mucosal healing status). Depending on the response status determined by the mapping tool, a subject may continue to receive an induction regimen or maintenance regimen of adalimumab.

In different clinical studies, the patients may be diagnosed with Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the cecum, or in both the cecum and transverse colon.

In different clinical studies, the patients may be diagnosed with illeocolonic Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the late jejunum or in the jejunum and transverse colon.

US11857669B2. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices (2024-01-02). BIORA THERAPEUTICS, INC. [US]. Inventors: Mitchell Lawrence Jones [US], Sharat Singh [US], Christopher Loren Wahl [US], Harry Stylli [US].
Full text: Click here
Patent 2024
Abdominal Pain Adalimumab Adrenal Cortex Hormones Biological Markers Biopsy BLOOD Cecum Colonoscopy C Reactive Protein Crohn Disease Cytokine Diarrhea Diet Endoscopy Endoscopy, Gastrointestinal Feces Homo sapiens Immunoglobulins Immunosuppressive Agents Jejunum Leukocyte L1 Antigen Complex Medical Devices Mesalamine Mucous Membrane Neoadjuvant Therapy Patient Care Management Patients Pharmaceutical Preparations Placebos Primary Care Physicians Safety Therapeutics Tissues Transverse Colon Treatment Protocols Tumor Necrosis Factor-alpha Ulcerative Colitis X-Ray Computed Tomography
2
COVID-19 Hyperinflammation Treatment Protocol

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
BLOOD Chest Congenital Abnormality COVID 19 C Reactive Protein Diverticulitis Extracorporeal Membrane Oxygenation Ferritin fibrin fragment D Intestines Lactate Dehydrogenase Lung Lymphocyte Noninvasive Ventilation Oxygen Oxygen Saturation Patients Training Programs
3
Oral Health Assessment and Pneumonia Risk
Cited 1 time
All patients admitted to our hospital received a basic oral health check, including OHAT, by a dental hygienist to identify those requiring dental treatment and oral care. OHAT was developed for regular oral assessment and protocolisation of oral care, in an attempt to provide equitable, high-quality oral care, regardless of the personnel administering care4 (link) and for objective assessment of the oral environment in clinical practice.
Patients with swallowing dysfunction are commonly referred to the Ear, Nose and Throat department for VE and VF, followed by treatment and rehabilitation.
This study included 24 patients (7 men and 17 women; age range: 64–97 years; average age: 86 years) who were examined by OHAT, VE and VF at Fukuoka Dental College Hospital between April 2014 and October 2019. Patients with head and neck cancers were excluded from the study, as these conditions may affect the oral environment.
A flow chart of patient selection is shown in Figure 1.

Flow chart of patient selection.

A diagnosis of pneumonia was made in cases fulfilling the following criteria: chest X-ray or chest computed tomography (CT) showing an alveolar infiltration shadow, with a fever of 37.5°C or higher and an abnormally high C-reactive protein level, a peripheral white blood cell count of more than 9000/µL and/or the presence of any two or more airway symptoms, such as sputum. We evaluated the associations of the OHAT score with VE and VF and compared the associations between patients with no or only a single episode of pneumonia (no/single-pneumonia episode group) and patients with multiple pneumonia episodes (multiple-pneumonia episode group).
Yamano T., Nishi K., Omori F., Wada K, & Naito T. (2023). Association Between Oral Health and Swallowing Function in the Elderly. Clinical Interventions in Aging, 18, 343-351.
Publication 2023
Cancer of Head and Neck Chest C Reactive Protein Dental Care Dental Health Services Diagnosis Fever Hygienist, Dental Leukocyte Count Nose Patients Pharynx Pneumonia Quality of Health Care Radiography, Thoracic Rehabilitation Sputum Woman X-Ray Computed Tomography
4
Appendicitis-MISC Score for Diagnosis
Both groups were evaluated using NSS parameters [10 (link)]. These parameters were;

sex

type (continuous or intermittent), duration and migration of abdominal pain

anorexia, bilious vomiting, pyrexia (body temperature ≥ 38.0 °C [11 (link)])

presence of localized right lower quadrant abdominal tenderness, guarding, gurgling, a positive heel drop test, and rebound tenderness in physical examination

leukocytosis (> 10.600/mm3), neutrophilia (> 75%), elevated C-reactive protein (CRP) levels (> 5 mg/L) in blood examination

scoliosis on the right side, localized air-fluid level, gas deposition in the right lower quadrant on standing abdominal radiography

appendix diameter (> 7 mm), presence of a thickened wall, and surrounding loculated fluid collection on US

Consistent with the previous study, an NSS score ≥ 12 was accepted as the cutoff level for the diagnosis of AA [10 (link)].
Both groups were compared by new parameters thought to be MISC-specific (fatigue (feeling extra tired [12 ]), headache, maximum body temperature, and total fever [11 (link)] days in the history, serum lymphocyte and platelet counts, serum procalcitonin (PRC), alanine transferase (ALT), CRP, and D-dimer value). Statistically significant parameters were included in the scoring. A scoring system named the Appendicitis–MISC Score (AMS) was created using eight new parameters including the NSS score.
Toker Kurtmen B., Ekemen Keles Y., Tekindal M.A., Koyluoglu G, & Yilmaz Ciftdogan D. (2023). Differentiating abdominal pain due to COVID-19 associated multisystem inflammatory syndrome from children with acute appendicitis: a score system. Pediatric Surgery International, 39(1), 151.
Publication 2023
Abdomen Alanine Appendicitis BLOOD Body Temperature C Reactive Protein Diagnosis Fever fibrin fragment D Headache Heel Lymphocyte Neutrophil Physical Examination Platelet Counts, Blood Procalcitonin Serum Transferase
5
NHANES Participant Characteristics Protocol
Information on participant age, sex, race and ethnicity, education, income, insurance status, medical history, and medication use was collected through household questionnaires. Race and ethnicity was not consistently reported in the NHANES (eg, Hispanic participants were not oversampled before 2007 and non-Hispanic Asian participants were not classified until 2011).24 For consistency over time, we categorized participants as self-reported Mexican American, non-Hispanic Black, non-Hispanic White, or other race and ethnicity (eg, non-Hispanic Asian or multiple). The family income-to-poverty ratio reflected annual family income relative to the federal poverty threshold and was used as a measure of income classified into 3 groups (≤100%, 101%-399%, and ≥400%).25 (link)Weight, height, waist circumference, and blood pressure (BP) were measured at mobile examination centers by trained staff according to standardized procedures.23 Body mass index was calculated as weight in kilograms divided by height in meters squared. Three BP measurements were assessed, and systolic BP and diastolic BP were calculated as the mean of all available measurements.
Participants were asked to provide blood samples at the mobile examination centers. The samples were stored at −20 °C and sent to central laboratories to determine lipid, plasma glucose, serum insulin, and C-reactive protein levels following standard protocols.23 A subset of participants were randomly selected to attend the morning session after an overnight fast; triglycerides, fasting plasma glucose (FPG), and insulin were measured for those who fasted at least 8 hours. Insulin resistance was assessed with the homeostasis model assessment score.26 (link) Although there were changes in the laboratories, methods, and instruments used to measure lipid levels,27 (link) all laboratories participated in the CDC Lipids Standardization Program,28 thus ensuring the accuracy, precision, and comparability of lipid measurements across cycles. To account for changes in laboratory methods over time, we calibrated FPG and serum insulin measurements to early cycles using the recommended backward equations.23
Wang J.S., Xia P.F., Ma M.N., Li Y., Geng T.T., Zhang Y.B., Tu Z.Z., Jiang L., Zhou L.R., Zhang B.F., Tong W.W., Shan Z., Liu G., Yang K, & Pan A. (2023). Trends in the Prevalence of Metabolically Healthy Obesity Among US Adults, 1999-2018. JAMA Network Open, 6(3), e232145.
Full text: Click here
Publication 2023
Asian Persons BLOOD Blood Pressure C Reactive Protein Determination, Blood Pressure Ethnicity Glucose Hispanics Homeostasis Households Index, Body Mass Insulin Insulin Resistance Lipids Mexican Americans Pharmaceutical Preparations Plasma Pressure, Diastolic Serum Systolic Pressure Triglycerides Waist Circumference

Top products related to «C Reactive Protein»

1
Cobas 6000 by Roche
Sourced in Switzerland, Germany, United States, Japan, Denmark, Italy, France, United Kingdom, Belgium, Norway, China, Israel, Poland, Netherlands, Sweden
The Cobas 6000 is an automated clinical chemistry and immunoassay analyzer system designed for high-volume laboratory testing. It combines the features of two separate instruments, the Cobas c 501 module for clinical chemistry and the Cobas e 601 module for immunoassays, into a single integrated platform. The Cobas 6000 system is capable of performing a wide range of diagnostic tests, including biochemical, immunological, and specialty assays.
2
Au5800 by Beckman Coulter
Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada
The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.
3
Bnii nephelometer by Siemens
Sourced in Germany, United States, Japan, United Kingdom, Switzerland
The BNII nephelometer is a laboratory instrument used for the measurement of protein concentrations in biological samples. It operates by directing a beam of light through a sample and detecting the scattered light, which is proportional to the concentration of particles in the sample. The BNII nephelometer provides quantitative data on the levels of specific proteins present in the analyzed solution.
4
Cobas 8000 by Roche
Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
5
Advia 1800 by Siemens
Sourced in Germany, United States, United Kingdom, Japan, Denmark
The ADVIA 1800 is a clinical chemistry analyzer designed for use in medical laboratories. It is capable of performing a wide range of common clinical chemistry tests on patient samples. The ADVIA 1800 automates the analysis process, providing efficient and accurate results to support patient diagnosis and treatment.
6
Elecsys 2010 by Roche
Sourced in Germany, Switzerland, United States, United Kingdom, France, Norway, Japan
The Elecsys 2010 is an automated immunoassay analyzer used for the in vitro determination of various analytes in biological samples. It is designed for high-throughput testing and offers precise and reliable results.
7
Enzyme linked immunosorbent assay by R&D Systems
Sourced in United States, United Kingdom, Germany
The enzyme-linked immunosorbent assay (ELISA) is a laboratory technique used to detect and quantify specific proteins, peptides, antibodies, or hormones in a sample. It utilizes the principle of antigen-antibody interactions to measure the concentration of a target analyte in a liquid sample.

More about "C Reactive Protein"

C-Reactive Protein (CRP) is a critical biomarker for monitoring inflammation, infection, and various health conditions.
As a sensitive acute-phase protein produced by the liver, CRP levels can indicate the presence and severity of cardiovascular disease, rheumatoid arthritis, cancer, and other inflammatory states.
Measuring CRP is crucial for diagnosis, treatment, and disease management.
CRP can be accurately quantified using reliable analytical platforms such as the Cobas 6000, AU5800, and BNII nephelometer systems.
These advanced instruments leverage immunoturbidimetric or nephelometric techniques to provide rapid, precise CRP measurements.
The Cobas 8000 and ADVIA 1800 analyzers are also commonly used for CRP testing, while the Elecsys 2010 employs an Enzyme-Linked Immunosorbent Assay (ELISA) approach.
PubCompare.ai, an innovative AI-driven platform, can optimize CRP research by identifying the best protocols and products from literature, preprints, and patents.
By utilizing AI-driven comparisons, PubCompare.ai helps researchers enhance the reproducibility and accuracy of their CRP studies, leading to improved research outcomes and valuable insights.
With its powerful tools and features, PubCompare.ai enables researchers to gain a deeper understanding of this crucial biomarker and advance their CRP-related investigations.